RxDoctor Payments Data

Rohit Sundrani

Cardiovascular Disease · Fresno, CANPI 1508835463

Payments from drug & device makers

$110,383in general payments, 2019–2025

Across 359 payments — averaging $307.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$39K
  • Abbott$29K
  • Amgen$24K
  • AstraZeneca$11K
  • Edwards Lifesciences$4K
  • Medtronic$3K
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$1,6502%
  • Speaking & faculty fees$63,41274%
  • Travel & lodging$11,09813%
  • Food & beverage$9,96612%
  • Education$760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,383 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,520,708
Medicare patients
4,519
Services billed
18,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban674$872,344
EliquisApixaban396$505,464
EntrestoSacubitril/Valsartan138$195,414
FarxigaDapagliflozin Propanediol124$115,360
Repatha SureclickEvolocumab114$96,942
BrilintaTicagrelor56$42,410
VascepaIcosapent Ethyl59$36,372
JardianceEmpagliflozin25$35,684
Metoprolol Succinate1,875$32,208
Icosapent Ethyl41$15,649
Atorvastatin Calcium1,190$13,494
Praluent PenAlirocumab15$12,956
LivaloPitavastatin Calcium13$9,923
Amiodarone Hcl163$9,721
NexlizetBempedoic Acid/Ezetimibe11$8,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$38,606$872,344674 claims
PfizerEliquis$43$505,464396 claims
AstraZenecaFarxiga, Brilinta$10,928$157,770180 claims
Boehringer IngelheimJardiance$21$35,68425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →